FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study
The FOLFOX-HAIC combined with targeted immunotherapy regimen is effective in patients with unresectable HCC, demonstrated by a high surgical conversion rate and manageable adverse effects. This regimen represents a potential novel first-line treatment option for HCC.
Authors
- Xuxiao Chen (ORCID: https://orcid.org/0000-0002-0743-5563)
- Yan-Cen Lu
- Fengjie Hao (ORCID: https://orcid.org/0000-0002-6734-265X)
- Yongjun Chen (ORCID: https://orcid.org/0000-0001-6136-6258)
- Junqing Wang (ORCID: https://orcid.org/0000-0002-9091-9891)
- Di Ma (ORCID: https://orcid.org/0000-0001-5067-874X)
- Yu-Chen Yang (ORCID: https://orcid.org/0009-0008-6504-9127)
Institutions
- Ruijin Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.3389/fimmu.2024.1471017
- Citations
- 15
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.54